PL2571503T3
(pl)
|
2010-05-14 |
2015-06-30 |
Dana Farber Cancer Inst Inc |
Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
|
CA2799381A1
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Male contraceptive compositions and methods of use
|
AU2011252799B2
(en)
|
2010-05-14 |
2015-05-14 |
Cold Spring Harbor Laboratory |
Compositions and methods for treating leukemia
|
EP2635279A4
(en)
*
|
2010-11-05 |
2014-10-29 |
Glaxosmithkline Ip No 2 Ltd |
CHEMICAL COMPOUNDS
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
AR084731A1
(es)
*
|
2010-12-06 |
2013-06-05 |
Piramal Life Sciences Ltd |
Derivados de imidazoquinolina sustituidos
|
EP2705039B1
(en)
|
2011-05-04 |
2017-07-26 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
US9328117B2
(en)
|
2011-06-17 |
2016-05-03 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
KR101800749B1
(ko)
|
2011-09-30 |
2017-11-24 |
주식회사 씨앤드씨신약연구소 |
신규한 헤테로사이클 유도체 및 그의 용도
|
WO2013097052A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
CN104334526A
(zh)
|
2012-04-20 |
2015-02-04 |
艾伯维公司 |
异吲哚酮衍生物
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
US9624244B2
(en)
|
2012-06-06 |
2017-04-18 |
Constellation Pharmaceuticals, Inc. |
Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
|
MX2014015156A
(es)
|
2012-06-12 |
2015-08-06 |
Abbvie Inc |
Derivados de piridinona y piridazinona.
|
EP2861255B1
(en)
|
2012-06-19 |
2019-10-09 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
US9422290B2
(en)
|
2012-11-13 |
2016-08-23 |
Boehringer Ingelheim International Gmbh |
Triazolopyridazine
|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
WO2014080290A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Cyclic amines as bromodomain inhibitors
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
MX2015007921A
(es)
|
2012-12-21 |
2016-03-03 |
Zenith Epigenetics Corp |
Compuestos heterociclicos novedosos como inhibidores de bromodominio.
|
WO2014128655A1
(en)
*
|
2013-02-25 |
2014-08-28 |
Aurigene Discovery Technologies Limited |
Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
|
WO2014164596A1
(en)
|
2013-03-11 |
2014-10-09 |
The Regents Of The University Of Michigan |
Bet bromodomain inhibitors and therapeutic methods using the same
|
CN105189515B
(zh)
|
2013-03-14 |
2018-07-03 |
葛兰素史克知识产权第二有限公司 |
作为溴结构域抑制剂的呋喃并吡啶类
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
MX367420B
(es)
|
2013-03-14 |
2019-08-21 |
Convergene Llc |
Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
|
ES2755827T3
(es)
|
2013-03-15 |
2020-04-23 |
Incyte Holdings Corp |
Heterciclos tricíclicos como inhibidores de proteína BET
|
JP2016519660A
(ja)
*
|
2013-03-15 |
2016-07-07 |
エピジェネティクス・インコーポレイテッド |
ブロモドメイン阻害剤としてのオキサゾロ[5,4−c]キノリン−2−オン化合物
|
WO2014154760A1
(en)
*
|
2013-03-27 |
2014-10-02 |
Boehringer Ingelheim International Gmbh |
Indolinone analogues as brd4 inhibitors
|
EP2978758B1
(en)
*
|
2013-03-27 |
2017-02-08 |
Boehringer Ingelheim International GmbH |
Dihydroquinazolinone analogues as brd4 inhibitors
|
TWI530499B
(zh)
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
AU2014256750B2
(en)
|
2013-04-26 |
2018-08-23 |
Beigene, Ltd. |
Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
SI2991683T1
(sl)
|
2013-05-02 |
2020-01-31 |
Glykos Finland Oy |
Konjugati glikoproteina ali glikana s toksično obremenitvijo
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
US8975417B2
(en)
*
|
2013-05-27 |
2015-03-10 |
Novartis Ag |
Pyrazolopyrrolidine derivatives and their use in the treatment of disease
|
ES2656471T3
(es)
*
|
2013-05-28 |
2018-02-27 |
Novartis Ag |
Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades
|
KR102307566B1
(ko)
*
|
2013-06-21 |
2021-10-05 |
제니쓰 에피제네틱스 리미티드 |
신규한 바이사이클릭 브로모도메인 억제제
|
CN105492439B
(zh)
|
2013-06-21 |
2019-11-22 |
齐尼思表观遗传学有限公司 |
作为溴结构域抑制剂的取代的双环化合物
|
JP2016523964A
(ja)
|
2013-07-08 |
2016-08-12 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Betタンパク質阻害剤としての三環式複素環
|
BR112016001457A2
(pt)
|
2013-07-25 |
2017-08-29 |
Dana Farber Cancer Inst Inc |
Inibidores de fatores de transcrição e usos dos mesmos
|
WO2015015318A2
(en)
|
2013-07-31 |
2015-02-05 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
WO2015049629A1
(en)
*
|
2013-10-01 |
2015-04-09 |
Piramal Enterprises Limited |
Imidazoquinoline compounds as bromodomain inhibitors
|
US9428513B2
(en)
|
2013-11-07 |
2016-08-30 |
Boehringer Ingelheim International Gmbh |
Triazolopyrazine
|
CA2929652A1
(en)
|
2013-11-08 |
2015-05-14 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
WO2015081203A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
US9108953B2
(en)
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
JP6262363B2
(ja)
*
|
2013-11-26 |
2018-01-17 |
ギリアード サイエンシーズ, インコーポレイテッド |
ブロモドメイン阻害剤としてのキノリン誘導体
|
WO2015092118A1
(en)
|
2013-12-17 |
2015-06-25 |
Orion Corporation |
Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
CA2934788C
(en)
|
2014-01-09 |
2021-12-07 |
Orion Corporation |
Bicyclic heterocyclic derivatives as bromodomain inhibitors
|
US10793571B2
(en)
|
2014-01-31 |
2020-10-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
WO2015117083A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
KR20160115953A
(ko)
|
2014-01-31 |
2016-10-06 |
다나-파버 캔서 인스티튜트 인크. |
디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
|
CN107074861A
(zh)
|
2014-02-28 |
2017-08-18 |
密执安大学评议会 |
作为bet溴结构域抑制剂的9h嘧啶并[4,5‑b]吲哚和相关类似物
|
CN106456653A
(zh)
|
2014-02-28 |
2017-02-22 |
腾沙治疗公司 |
高胰岛素血症相关病症的治疗
|
UA119870C2
(uk)
|
2014-04-23 |
2019-08-27 |
Інсайт Корпорейшн |
1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
|
NO2714752T3
(hr)
*
|
2014-05-08 |
2018-04-21 |
|
|
US9428515B2
(en)
*
|
2014-05-09 |
2016-08-30 |
Boehringer Ingelheim International Gmbh |
Benzimidazole derivatives
|
HUE043441T2
(hu)
|
2014-06-20 |
2019-08-28 |
Constellation Pharmaceuticals Inc |
2-((4S)-6-(4-klórfenil)-l-metil-4H-benzo[c]izoxazolo[4,5-e]azepin-4-il)acetamid kristályos formái
|
DK3160513T3
(da)
|
2014-06-30 |
2020-04-06 |
Glykos Finland Oy |
Saccharidderivat af en toksisk payload og antistofkonjugater deraf
|
MX2017001756A
(es)
|
2014-08-08 |
2017-05-30 |
Dana Farber Cancer Inst Inc |
Derivados de diazepano y sus usos.
|
BR112017002190A2
(pt)
|
2014-08-08 |
2017-11-21 |
Dana Farber Cancer Inst Inc |
derivados de di-hidropteridinona e usos dos mesmos
|
US9527864B2
(en)
|
2014-09-15 |
2016-12-27 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
KR20170068597A
(ko)
|
2014-10-27 |
2017-06-19 |
텐샤 세러퓨틱스 인코포레이티드 |
브로모도메인 저해제
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
WO2016087942A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridines as bromodomain inhibitors
|
CN107207474B
(zh)
|
2014-12-11 |
2021-05-07 |
恒翼生物医药科技(上海)有限公司 |
被取代的杂环作为溴结构域抑制剂
|
US10231953B2
(en)
|
2014-12-17 |
2019-03-19 |
Zenith Epigenetics Ltd. |
Inhibitors of bromodomains
|
US10259809B2
(en)
|
2015-02-03 |
2019-04-16 |
Trillium Therapeutics Inc. |
Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
|
US10307407B2
(en)
|
2015-02-27 |
2019-06-04 |
The Regents Of The University Of Michigan |
9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
SG10202002181UA
(en)
|
2015-04-02 |
2020-05-28 |
Merck Patent Gmbh |
Imidazolonyl quinolines and use thereof as atm kinase inhibitors
|
WO2016186453A1
(en)
*
|
2015-05-20 |
2016-11-24 |
Kainos Medicine, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
WO2016199943A1
(en)
*
|
2015-06-11 |
2016-12-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CN107709298A
(zh)
|
2015-06-16 |
2018-02-16 |
奥赖恩公司 |
作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
KR20180035785A
(ko)
|
2015-06-26 |
2018-04-06 |
텐샤 세러퓨틱스 인코포레이티드 |
Nut 중간선 암종의 치료
|
US20180312496A1
(en)
|
2015-07-02 |
2018-11-01 |
Orion Corporation |
Bicyclic heterocycle derivatives as bromodomain inhibitors
|
PE20181088A1
(es)
|
2015-08-10 |
2018-07-09 |
Dana Farber Cancer Inst Inc |
Mecanismo de resistencia a inhibidores de bromodominio bet
|
WO2017024406A1
(en)
|
2015-08-11 |
2017-02-16 |
Neomed Institute |
N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
|
JP2018527340A
(ja)
|
2015-08-11 |
2018-09-20 |
ネオメド インスティテュートNeomed Institute |
アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用
|
KR20180039669A
(ko)
|
2015-08-12 |
2018-04-18 |
네오메드 인스티튜트 |
치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
|
JP2018526424A
(ja)
|
2015-09-11 |
2018-09-13 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
|
PE20181287A1
(es)
|
2015-09-11 |
2018-08-07 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
RU2018112312A
(ru)
|
2015-09-22 |
2019-10-23 |
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед |
Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
|
US10501459B2
(en)
|
2015-10-21 |
2019-12-10 |
Neomed Institute |
Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
|
AR106520A1
(es)
|
2015-10-29 |
2018-01-24 |
Incyte Corp |
Forma sólida amorfa de un inhibidor de proteína bet
|
PE20181298A1
(es)
|
2015-11-25 |
2018-08-07 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos
|
AU2016361441B2
(en)
*
|
2015-11-25 |
2021-08-12 |
Convergene Llc |
Bicyclic BET bromodomain inhibitors and uses thereof
|
WO2017127930A1
(en)
|
2016-01-28 |
2017-08-03 |
Neomed Institute |
Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
|
WO2017142881A1
(en)
|
2016-02-15 |
2017-08-24 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
|
JP7001614B2
(ja)
|
2016-04-06 |
2022-02-03 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
リガンド依存性の標的タンパク質分解のための単官能性中間体
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
WO2017174621A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridyl derivatives as bromodomain inhibitors
|
JP6954920B2
(ja)
|
2016-04-07 |
2021-10-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
ブロモドメイン阻害薬としてのベンゾ[b]フラン
|
US10633386B2
(en)
|
2016-04-12 |
2020-04-28 |
The Regents Of The University Of Michigan |
BET protein degraders
|
UA124764C2
(uk)
|
2016-04-15 |
2021-11-17 |
Еббві Інк. |
Інгібітори бромодомену
|
AU2017269673A1
(en)
|
2016-05-24 |
2018-11-22 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridine dicarboxamide derivatives as bromodomain inhibitors
|
CN114366748A
(zh)
|
2016-06-20 |
2022-04-19 |
因赛特公司 |
Bet抑制剂的结晶固体形式
|
WO2018022802A1
(en)
|
2016-07-26 |
2018-02-01 |
University Of Southern California |
Selective bromodomain inhibition of fungal bdf1
|
US9957233B1
(en)
|
2016-08-05 |
2018-05-01 |
Calitor Sciences, Llc |
Process for preparing substituted quinolin-4-ol compounds
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
US11466028B2
(en)
|
2016-09-13 |
2022-10-11 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as BET protein degraders
|
US10975093B2
(en)
|
2016-09-13 |
2021-04-13 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as BET protein degraders
|
WO2018109271A1
(en)
|
2016-12-13 |
2018-06-21 |
Orion Corporation |
New bromodomain inhibitors
|
WO2018144789A1
(en)
|
2017-02-03 |
2018-08-09 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as bet bromodomain inhibitors
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
CN109384784B
(zh)
*
|
2017-08-10 |
2021-01-12 |
浙江海正药业股份有限公司 |
磺酰胺类衍生物、其制备方法及其在医药上的用途
|
US11267822B2
(en)
|
2017-09-13 |
2022-03-08 |
The Regents Of The University Of Michigan |
BET bromodomain protein degraders with cleavable linkers
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
US20230014730A1
(en)
|
2019-09-23 |
2023-01-19 |
Nanjing Zhengxiang Pharmaceuticals Co., Ltd. |
Phosphodiesterase inhibitors and use
|
EP4087843A1
(en)
*
|
2020-01-10 |
2022-11-16 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
US11530218B2
(en)
|
2020-01-20 |
2022-12-20 |
Incyte Corporation |
Spiro compounds as inhibitors of KRAS
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
CA3179692A1
(en)
*
|
2020-04-16 |
2021-10-21 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
EP4236942A1
(en)
*
|
2020-10-27 |
2023-09-06 |
Arena Pharmaceuticals, Inc. |
Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
US20230174555A1
(en)
*
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
IL312114A
(en)
|
2021-10-14 |
2024-06-01 |
Incyte Corp |
Quinoline compounds as Kras inhibitors
|
WO2023205251A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution A/S |
Compounds active towards bromodomains
|